Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
Other Sizes |
|
Purity: ≥98%
Lamotrigine (Lamictal, BW 430C; BW430C; Crisomet, Lamictin, Lamitor), an approved anti-convulsant drug used in the treatment of epilepsy and bipolar disorder, is an inhibitor of 5-HT with IC50 of 240 μM and 474 μM in human platelets and rat brain synaptosomes. Moreover, lamotrigine blocks sodium channels.
Targets |
Sodium channel; 5-HT (human platelets) ( IC50 = 240 μM ); 5-HT (rat brain synaptosomes) ( IC50 = 474 μM )
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C9H7CL2N5
|
|
---|---|---|
Molecular Weight |
256.09
|
|
Exact Mass |
255.01
|
|
Elemental Analysis |
C, 42.21; H, 2.76; Cl, 27.69; N, 27.35
|
|
CAS # |
84057-84-1
|
|
Appearance |
White to off-white solid powder
|
|
SMILES |
C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
|
|
InChi Key |
PYZRQGJRPPTADH-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)
|
|
Chemical Name |
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.9049 mL | 19.5244 mL | 39.0488 mL | |
5 mM | 0.7810 mL | 3.9049 mL | 7.8098 mL | |
10 mM | 0.3905 mL | 1.9524 mL | 3.9049 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04770493 | Recruiting | Drug: Lamotrigine Drug: Placebo |
Alcohol Use Disorder | Brown University | January 24, 2022 | Phase 2 |
NCT05639257 | Recruiting | Drug: Lamotrigine Drug: Namuscla |
Non-Dystrophic Myotonia | Grete Andersen, MD | December 5, 2022 | Not Applicable |
NCT05450978 | Recruiting | Drug: Lamotrigine Drug: Levetiracetam |
Epilepsy Pregnancy Related |
Page B. Pennell, MD | July 20, 2022 | N/A |
NCT05450822 | Recruiting | Drug: Levetiracetam Drug: Lamotrigine tablet |
Epilepsy | Gitte Moos Knudsen | February 18, 2022 | N/A |
NCT06184581 | Not yet recruiting | Drug: Lithium Carbonate Drug: Lamotrigine |
Bipolar II Disorder | Mental Health Services in the Capital Region, Denmark |
March 1, 2024 | Phase 4 |